Abstract: The implantable device includes a core including a core polymer matrix within which is dispersed one or more therapeutic agents. The core polymer matrix includes a hydrophobic polymer comprising a first poly ortho ester (POE) polymer. The POE polymer has a Tg of between about ?20° C. and 40° C. as determined in accordance with ASTM E1640-18. Methods for treating conditions in a patient in need thereof are also provided.

Abstract: An implantable device for the delivery of a therapeutic agent is provided. The implantable device includes a core having a core polymer matrix within which is dispersed one or more therapeutic agents. The core polymer matrix includes a hydrophobic polymer comprising a first poly ortho ester (POE) polymer. The first POE polymer has a Tg of between about ?20° C. and 40° C. as determined in accordance with ASTM E1640-18. Methods for forming the implantable device are also provided.

Abstract: An injectable composition for delivering a therapeutic agent is provided. The injectable composition includes one or more polymers including a poly ortho ester (POE) polymer. The POE polymer has a Tg of between about ?10° C. and 110° C. as determined in accordance with ASTM E1640-18. The injectable composition also includes one or more solvents and one or more therapeutic agents. The one or more therapeutic agents includes a basic therapeutic agent. Methods for treating a condition in a patient are also provided.

Abstract: An implantable device for delivery of a therapeutic agent is provided. The device includes a core including a core polymer matrix within which is dispersed a therapeutic agent. The therapeutic agent includes one or more GnRH agonist or antagonists or antagonists. The core polymer matrix includes an ethylene vinyl acetate copolymer having a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and/or a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.

Abstract: Orally adhering lozenges comprising soluble dietary fiber are provided herein. The orally adhering lozenges provided herein may be in the form of tablet-type lozenges comprising compressed powders and/or granules in at least two layers. The orally adhering lozenges include at least 30% soluble dietary fiber. The orally adhering lozenges also include an adhesive component to adhere the lozenge inside the mouth. The orally adhering lozenges are also low in cariogenic sugar, non-resistant starch, and polyols.

Abstract: An implantable device for delivery of a therapeutic agent is provided. The device includes a core including a core polymer matrix within which is dispersed a therapeutic agent. The therapeutic agent includes one or more GLP-1 receptor agonists. The core polymer matrix includes an ethylene vinyl acetate copolymer having a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and/or a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.

Abstract: An analyte sensor is disclosed. The analyte sensor includes an implantable sensor configured to measure a signal indicative of an analyte concentration in a user and at least one membrane layer. The membrane layer is disposed over at least a portion of the sensor. The membrane includes a membrane polymer matrix including an ethylene vinyl acetate copolymer and a therapeutic agent dispersed within the membrane polymer matrix. The membrane layer is permeable to an analyte. Devices and methods for monitoring analytes are also disclosed.

Abstract: An implantable device for intratumoral delivery of a therapeutic agent is provided. The implantable device includes a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents. The therapeutic agent(s) includes one or more antibodies. Optionally, the polymer matrix includes one or more excipients. The polymer matrix includes a hydrophobic polymer. The hydrophobic polymer has a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms and/or a melting temperature of from about 20° C. to about 70° C. as determined in accordance with ASTM D3418-21.

Abstract: An implantable medical device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more antipsychotics. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a melt flow index of about 1 to about 400 grams per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms.

Abstract: An implantable medical device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more aromatase inhibitors. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

Abstract: An intravaginal ring device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more aromatase inhibitors. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a vinyl acetate content of from about 10 wt. % to about 60 wt. % and/or a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

Abstract: An implantable and refillable device for delivering a drug compound is provided. The device comprises a reservoir within which the drug compound is capable of being retained, wherein the reservoir defines a first surface and a second surface opposing the first surface. A release structure comprising a hydrophobic polymer surrounds at least a portion of the reservoir. The release structure is in communication with the reservoir such that the drug compound can pass from the reservoir through the release structure. A septum is positioned adjacent to the first surface of the reservoir and a backing layer is positioned adjacent to the second surface of the reservoir.

Abstract: An oral adhering lozenge is provided which delivers to the mouth a component with an undesirable flavor and a component for delivering a masking flavor. The oral adhering lozenge comprises a first, adherent layer and a second layer. The first, adherent layer includes a flavor-masking component, and the second layer includes both an active component and a flavor-masking component. In another configuration, the first, adherent layer includes both an active component and a flavor-masking component. In use, the second layer of the lozenge generally finishes dissolving and/or eroding in the mouth before the first layer finishes dissolving and/or eroding. The later eroding adherent layer will continue to release the flavor-masking component after all of the active component has been released into the mouth, thereby providing increased masking of any bitter aftertaste of the active.

Abstract: An implantable and refillable device for delivering a contraceptive agent is provided. The device comprises a reservoir within which the contraceptive agent is capable of being retained, wherein the reservoir defines a first surface and a second surface opposing the first surface. A release structure comprising a hydrophobic polymer surrounds at least a portion of the reservoir. The release structure is in communication with the reservoir such that the contraceptive agent can pass from the reservoir through the release structure. A septum is positioned adjacent to the first surface of the reservoir and a backing layer is positioned adjacent to the second surface of the reservoir.

Abstract: An oral adhering lozenge is provided which delivers to the mouth a component with an undesirable flavor and a component for delivering a masking flavor. The oral adhering lozenge comprises a first, adherent layer and a second layer. The first, adherent layer includes a flavor-masking component, and the second layer includes both an active component and a flavor-masking component. In another configuration, the first, adherent layer includes both an active component and a flavor-masking component. In use, the second layer of the lozenge generally finishes dissolving and/or eroding in the mouth before the first layer finishes dissolving and/or eroding. The later eroding adherent layer will continue to release the flavor-masking component after all of the active component has been released into the mouth, thereby providing increased masking of any bitter aftertaste of the active.

Abstract: A system for detecting when two people are in a vehicle. The system detects the presence of two warm bodies with one or two infrared cameras.

Abstract: A system for detecting when two people are in a vehicle. The system detects the presence of two warm bodies with one or two infrared cameras.

Abstract: A multi-layer film or laminate is disclosed in which an olefinic polymer layer is adhered to a metal foil layer without the use of an adhesive. The olefinic polymer layer contains an olefinic polymer in combination with a transition metal salt. The addition of the transition metal salt greatly improves the peel strength of the laminate.

Abstract: A system for reducing traffic accidents caused by distraction from a mobile telecom device. The system detects when the device is near a driver's seat of a moving vehicle. While the system is carrying a voice call between a remote voice device and the mobile device, the system modifies voice signal transmission between the devices by periodically playing a beep or other signal to remind the parties that one of them is driving and suspends voice signal transmission from the remote device to the mobile device when the system detects that circumstances affecting level of attention required for driving merit the driver paying greater attention.

Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.